Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP (TD-2)

This study has been completed.
Sponsor:
Collaborator:
Elizabeth Glaser Pediatric AIDS Foundation
Information provided by (Responsible Party):
Benjamin Chi, MD, MSc, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT00204308
First received: September 12, 2005
Last updated: May 30, 2012
Last verified: May 2012

September 12, 2005
May 30, 2012
March 2005
May 2007   (final data collection date for primary outcome measure)
maternal antiretroviral drug resistance to non-nucloeoside reverse transcriptase inhibitors [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Frequency of maternal NNRTI resistance mutations at 6 weeks post-ingestion
Complete list of historical versions of study NCT00204308 on ClinicalTrials.gov Archive Site
  • maternal antiretroviral drug resistance to non-nucloeoside reverse transcriptase inhibitors [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
  • maternal hematological and renal function after TDF-FTC use [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
  • Frequency of maternal NNRTI resistance mutations at 2 weeks post-ingestion
  • Safety of TDF and FTC when used in pregnancy as a single-dose
Not Provided
Not Provided
 
Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP
Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission

The purpose of this study is to determine whether the addition of tenofovir (TDF) and emtricitabine (FTC)to a standard PMTCT regimen containing single-dose nevirapine (NVP) can reduce the development of post-ingestion HIV resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Single-dose intrapartum and neonatal nevirapine (NVP), either alone or in combination with short course zidovudine (ZDV) is in widespread use to prevent mother-to-child HIV transmission throughout the developing world. Though the public health benefits cannot be overstated, widespread use of NVP in this fashion may come at a cost. Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations are induced in at least 20% and probably a larger proportion of women exposed to NVP in this fashion. Addition of short-course ZDV does not appear to mitigate this effect substantially. The full implications of these NVP resistance mutations are yet unknown, though there is concern that they may result in reduced efficacy of the NVP or other NNRTIs in long-term, therapeutic regimens.

We are conducting a clinical trial of tenofovir (TDF) and emtricitabine (FTC), marketed as a fixed dose combination, Truvada ™, to reduce NNRTI-resistance post-delivery in the setting of NVP with or without ZDV for PMTCT. TDF and FTC are both Category B drugs and are approved for use in pregnancy. They have several characteristics that make them ideal candidate drugs for use in conjunction with NVP, including long intracellular half-lives and established safety profile among adults for HIV treatment.

Women will be enrolled between 28 and 38 weeks of gestation. As part of normal PMTCT services, they may choose NVP-boosted ZDV or single dose NVP for PMTCT; We anticipate that most (~80%) will choose the former. At arrival for delivery, they will be randomized to receive either the two study drugs (intervention) or no drug (control). A total of 400 women will be randomized, and followed, along with their infants, for 6 months.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • HIV
  • Pregnancy
Drug: Combination tenofovir-emtricitabine
Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
Other Name: Truvada
  • Experimental: combination tenofovir-emtricitabine
    Intervention: Drug: Combination tenofovir-emtricitabine
  • No Intervention: control arm

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
400
May 2007
May 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Serologically confirmed HIV infection;
  • Gestational age of 28 to 38 weeks;
  • Previous selection of a NVP-based PMTCT regimen (with or without ZDV)
  • Willingness to participate in a randomized trial;
  • Willingness to follow up in a postpartum visit schedule;
  • Willingness to allow her infant to participate in this trial;

Exclusion Criteria:

  • Use of antiretroviral medications before this pregnancy, even in a single dose.
  • Current use of antiretroviral medications for treatment of advanced HIV disease and/or AIDS
  • Illness or complication of pregnancy likely to warrant transfer to the University Teaching Hospital (UTH), known at time of randomization;
  • Known or suspected allergy to NVP or other benzodiazepine medications;
  • History of known liver disease.
  • Hemoglobin level of 7.9 g/dL or less
Female
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Zambia
 
NCT00204308
EGSA 19-02
Yes
Benjamin Chi, MD, MSc, University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
Elizabeth Glaser Pediatric AIDS Foundation
Principal Investigator: Jeffrey S A Stringer, MD University of Alabama at Birmingham
Study Director: Benjamin H Chi, MD University of Alabama at Birmingham
University of North Carolina, Chapel Hill
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP